Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca and Selection of a New Pre-Clinically Validated

Regulus Announces Significant Progress in Strategic Alliance with AstraZeneca
   and Selection of a New Pre-Clinically Validated microRNA Oncology Target

PR Newswire

LA JOLLA, Calif., Oct. 28, 2013

LA JOLLA, Calif., Oct. 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc.
(NASDAQ: RGLS), a biopharmaceutical company leading the discovery and
development of innovative medicines targeting microRNAs, announced today the
selection of an undisclosed oncology target by AstraZeneca under the strategic
alliance to discover, develop, and commercialize microRNA therapeutics.
Regulus and AstraZeneca continue to collaborate on three exclusive microRNA
targets in cardiovascular and metabolic diseases and oncology.

"We are very pleased with the successful relationship we have built with
AstraZeneca and their selection of a validated microRNA target for oncology
indications," said Neil W. Gibson, Ph.D., Chief Scientific Officer of
Regulus. "In the last year, we have made significant progress in advancing
our drug discovery efforts against the portfolio of AstraZeneca targets. With
the support of AstraZeneca's drug development expertise and commitment to the
RNA therapeutics field, we continue to harness our microRNA expertise to
develop innovative, first-in-class treatment options for patients in need."

In August 2012, Regulus and AstraZeneca formed a strategic alliance focused on
three exclusive microRNA targets for cardiovascular and metabolic diseases and
oncology, which includes Regulus' program targeting microRNA-33 for the
treatment of atherosclerosis. Under the terms of the alliance, Regulus will
lead preclinical development and, if successful, could receive preclinical
milestone payments. AstraZeneca will lead and fund the clinical development
and commercialization of these programs. In addition, Regulus could also
receive clinical milestones based on the successful development of microRNA
therapies in each target area. Regulus is also eligible to receive significant
launch and commercial milestone payments and royalties contingent on the
successful commercialization of microRNA therapeutic products by AstraZeneca.

About Regulus Therapeutics Inc.

Regulus Therapeutics Inc. (NASDAQ:RGLS) is a biopharmaceutical company leading
the discovery and development of innovative medicines targeting
microRNAs.Regulus is uniquely positioned to leverage a mature therapeutic
platform that harnesses the oligonucleotide drug discovery and development
expertise of Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc.,
which founded the company. Regulus has a well-balanced microRNA therapeutic
pipeline entering clinical development, an emerging microRNA biomarkers
platform to support its therapeutic programs, and a rich intellectual property
estate to retain its leadership in the microRNA field. Regulus intends to
focus its proprietary efforts on developing microRNA therapeutics for oncology
indications and orphan diseases and is currently advancing several programs
toward clinical development in oncology, fibrosis and metabolic diseases.
Regulus is also developing RG-101, a GalNAc-conjugated anti-miR targeting
microRNA-122, for the treatment of chronic hepatitis C virus infection.
Regulus' commitment to innovation and its leadership in the microRNA field
have enabled the formation of strategic alliances with AstraZeneca,
GlaxoSmithKline and Sanofi. In addition, Regulus has formed a research
collaboration with Biogen Idec around its emerging microRNA biomarkers

For more information, please visit

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that
focuses on the discovery, development and commercialisation of prescription
medicines, primarily for the treatment of cardiovascular, metabolic,
respiratory, inflammation, autoimmune, oncology, infection and neuroscience
diseases. AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. For more information
please visit:

Forward-Looking Statements

Statements contained in this press release regarding matters that are not
historical facts are "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995, including statements
associated with Regulus' expectations regarding future therapeutic and
commercial potential of Regulus' business plans, technologies and intellectual
property related to microRNA therapeutics being discovered and developed by
Regulus. Because such statements are subject to risks and uncertainties,
actual results may differ materially from those expressed or implied by such
forward-looking statements. Words such as "believes," "anticipates," "plans,"
"expects," "intends," "will," "goal," "potential" and similar expressions are
intended to identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be incorrect. Actual
results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks
and uncertainties, which include, without limitation, risks associated with
the process of discovering, developing and commercializing drugs that are safe
and effective for use as human therapeutics, and in the endeavor of building a
business around such drugs. These and other risks concerning Regulus'
programs are described in additional detail in Regulus' SEC filings. All
forward-looking statements contained in this press release speak only as of
the date on which they were made. Regulus undertakes no obligation to update
such statements to reflect events that occur or circumstances that exist after
the date on which they were made.

SOURCE Regulus Therapeutics Inc.

Contact: Amy Conrad, Director, Investor Relations and Corporate
Communications,, 858-202-6321; Media: Liz Bryan,
Spectrum Science,, 202-955-6222 x2526
Press spacebar to pause and continue. Press esc to stop.